human pdac cell lines s2-013  (BioResource International Inc)

Journal: Oncotarget

Article Title: Efficient delivery of small interfering RNAs targeting particular mRNAs into pancreatic cancer cells inhibits invasiveness and metastasis of pancreatic tumors

doi: 10.18632/oncotarget.26880

Figure Lengend Snippet: ( A ) Whole-body in vivo imaging of the S2-013 tumor-bearing mice after intravenous injection of Alexa 647-labeled scrambled control siRNA-COL and Alexa 647-labeled scrambled control siRNA-FA-PEG-COL nanoparticles via the tail vein. Fluorescence intensity of the Alexa 647-labeled nanoparticles, which accumulated in S2-013-derived PDAC tumors, was measured 24 h after intravenous injection into the mice. ( B ) The S2-013 tumor-bearing mice were fixed by perfusion 24 h after intravenous injection of Alexa 647-labeled scrambled control siRNA-COL and Alexa 647-labeled scrambled control siRNA-FA-PEG-COL nanoparticles via the tail vein. Representative confocal immunofluorescence microscopic images of frozen sections of S2-013-derived PDAC tumor tissues from mice showing scrambled control siRNA-COL (red) and the siRNA-FA-PEG-COL nanoparticles (red). Blue, DAPI staining. Scale bars, 10 μm.

Article Snippet: The human PDAC cell line S2-013, which is a subline of SUIT-2, the human PDAC cell line PANC-1, and HPNE immortalized normal pancreatic epithelial cells were maintained in Dulbecco’s modified Eagle’s medium (Gibco-BRL, Carlsbad, CA, USA) containing 10% fetal calf serum as published previously [ ].

Techniques: In Vivo Imaging, Injection, Labeling, Control, Fluorescence, Derivative Assay, Immunofluorescence, Staining

Journal: Oncotarget

Article Title: Efficient delivery of small interfering RNAs targeting particular mRNAs into pancreatic cancer cells inhibits invasiveness and metastasis of pancreatic tumors

doi: 10.18632/oncotarget.26880

Figure Lengend Snippet: ( A ) Ex vivo images of the PDAC tumors excised from the S2-013 tumor-bearing mice after intravenous injection of Alexa 647-labeled scrambled control siRNA-FA-PEG-COL nanoparticles (Scr), Alexa 647-labeled CCDC88A siRNA-FA-PEG-COL nanoparticles (siCCDC88A), and Alexa 647-labeled WASF2 siRNA-FA-PEG-COL nanoparticles (siWASF2) via the tail vein. The peritoneal dissemination nodule and mouse heart were excised from the S2-013 tumor-bearing mice after intravenous injection of Alexa 647-labeled scrambled control siRNA-FA-PEG-COL nanoparticles. Fluorescence intensity of the Alexa 647-labeled nanoparticles was measured 24 h after intravenous injection to the mouse model. ( B ) The S2-013 tumor-bearing mice were fixed by perfusion 24 h after intravenous injection of Alexa 647-labeled scrambled control siRNA-FA-PEG-COL nanoparticles (Scr) or Alexa 647-labeled target siRNA-FA-PEG-COL nanoparticles against CCDC88A (siCCDC88A) and WASF2 (siWASF2) via the tail vein. Frozen sections of S2-013-derived PDAC tumor tissues were immunocytochemically stained with antibodies corresponding to the target siRNAs (green). Nanoparticles were indicated by red. Representative confocal immunofluorescence microscopic images are shown. Arrows, tumor cells showing suppression of the target proteins by the siRNA-FA-PEG-COL nanoparticles. Arrows, the target siRNA-FA-PEG-COL nanoparticle transfected tumor cells that suppress CCDC88A or WASF2. Arrowheads, the scrambled control siRNA-FA-PEG-COL nanoparticle transfected tumor cells that express CCDC88A and WASF2. Blue, DAPI staining. Scale bars, 10 μm.

Article Snippet: The human PDAC cell line S2-013, which is a subline of SUIT-2, the human PDAC cell line PANC-1, and HPNE immortalized normal pancreatic epithelial cells were maintained in Dulbecco’s modified Eagle’s medium (Gibco-BRL, Carlsbad, CA, USA) containing 10% fetal calf serum as published previously [ ].

Techniques: Ex Vivo, Injection, Labeling, Control, Fluorescence, Derivative Assay, Staining, Immunofluorescence, Transfection

Journal: Oncotarget

Article Title: Efficient delivery of small interfering RNAs targeting particular mRNAs into pancreatic cancer cells inhibits invasiveness and metastasis of pancreatic tumors

doi: 10.18632/oncotarget.26880

Figure Lengend Snippet: ( A ) Development of carcinomatosis in S2-013 tumor-bearing mice treated with scrambled control siRNA-FA-PEG-COL nanoparticles. Arrow, primary tumor; arrowheads, dissemination nodules in the abdominal cavity. ( B – D ) Hematoxylin and eosin staining of representative sections of S2-013-derived PDAC tumor tissues in mice treated with scrambled control siRNA-FA-PEG-COL nanoparticles showing areas of regional invasion of the retroperitoneum (B), and distant metastases to the liver (C) and lung (D). Original magnification: × 200

Article Snippet: The human PDAC cell line S2-013, which is a subline of SUIT-2, the human PDAC cell line PANC-1, and HPNE immortalized normal pancreatic epithelial cells were maintained in Dulbecco’s modified Eagle’s medium (Gibco-BRL, Carlsbad, CA, USA) containing 10% fetal calf serum as published previously [ ].

Techniques: Control, Staining, Derivative Assay

Journal: Oncotarget

Article Title: Efficient delivery of small interfering RNAs targeting particular mRNAs into pancreatic cancer cells inhibits invasiveness and metastasis of pancreatic tumors

doi: 10.18632/oncotarget.26880

Figure Lengend Snippet: ( A ) Representative S2-013-derived PDAC tumor tissues in S2-013 tumor-bearing mice treated with scrambled control siRNA-FA-PEG-COL nanoparticles (Scr) and target siRNA-FA-PEG-COL nanoparticles against mRNAs for LAMTOR2 (siLAMTOR2), mTOR (simTOR), and NUP85 (siNUP85). Arrow, primary tumor; arrowheads, dissemination nodules in the abdominal cavity. ( B ) Hematoxylin and eosin staining of representative sections of S2-013-derived PDAC tumor tissues in mice treated with scrambled control siRNA-FA-PEG-COL nanoparticles or target siRNA-FA-PEG-COL nanoparticles against mRNAs for LAMTOR2 , mTOR , and NUP85 .

Article Snippet: The human PDAC cell line S2-013, which is a subline of SUIT-2, the human PDAC cell line PANC-1, and HPNE immortalized normal pancreatic epithelial cells were maintained in Dulbecco’s modified Eagle’s medium (Gibco-BRL, Carlsbad, CA, USA) containing 10% fetal calf serum as published previously [ ].

Techniques: Derivative Assay, Control, Staining

Journal: Cancer Science

Article Title: Downregulation of 15‐hydroxyprostaglandin dehydrogenase by interleukin‐1β from activated macrophages leads to poor prognosis in pancreatic cancer

doi: 10.1111/cas.13467

Figure Lengend Snippet: Low 15‐hydroxyprostaglandin dehydrogenase (15‐ PGDH ) expression is implicated in poor pancreatic ductal adenocarcinoma ( PDAC ) prognosis. A, Workflow diagram of patients who underwent pancreatic resection and contributed samples for immunohistochemical ( IHC ) analysis. B, Representative IHC staining of 15‐ PGDH expression in 107 PDAC tissues. Scale bar = 100 μm. C,D, Relationship between 15‐ PGDH expression and relapse‐free survival (C) or overall survival (D) using the Kaplan‐Meier method

Article Snippet: The human PDAC cell lines PK‐8 and S2‐013 were obtained from the Japanese Collection of Research Bioresource Cell Bank (Ibaraki, Japan) and RIKEN Bioresource Center Cell Bank (Tsukuba, Japan).

Techniques: Expressing, Immunohistochemical staining, Immunohistochemistry

Journal: Cancer Science

Article Title: Downregulation of 15‐hydroxyprostaglandin dehydrogenase by interleukin‐1β from activated macrophages leads to poor prognosis in pancreatic cancer

doi: 10.1111/cas.13467

Figure Lengend Snippet: 15‐Hydroxyprostaglandin dehydrogenase (15‐ PGDH ) downregulation by interleukin‐1β ( IL ‐1β) enhances pancreatic ductal adenocarcinoma cell growth. A,B, Expression of HPGD (the gene coding 15‐ PGDH protein, upper panel) or 15‐ PGDH (lower panel) in PK ‐8 cells (A) or S2‐013 cells (B) after treatment with si RNA targeting 15‐ PGDH or with control si RNA , evaluated by quantitative RT ‐ PCR (upper panel) or Western blot analysis (lower panel). Data are presented as the treated/control cell ratio. C,D, PK ‐8 cells (C) or S2‐013 cells (D) transfected with si RNA s targeting 15‐ PGDH or with control si RNA were incubated for up to 96 hours and assayed for cell number; data are presented as the treated/control (time = 0) cell ratio. E,F, Expression of 15‐ PGDH in PK ‐8 cells or S2‐013 cells after IL ‐1β (E) or tumor necrosis factor‐α ( TNF ‐α) (F) treatment for 24 and 48 hours and distilled water treatment for 48 hours as a control was evaluated by Western blotting. G, Column graph showing relative 15‐ PGDH levels in PK ‐8 cells or S2‐013 cells after IL ‐1β and TNF ‐α treatment for 24 and 48 hours, and distilled water treatment for 48 hours as a control, were evaluated using ImageJ software. H, Expression of HPGD and IL 1B in six PDAC patients determined by quantitative RT ‐ PCR . Data were normalized to the ACTB mRNA level and are shown as the mean ± SD of three independent experiments. **P < .01

Article Snippet: The human PDAC cell lines PK‐8 and S2‐013 were obtained from the Japanese Collection of Research Bioresource Cell Bank (Ibaraki, Japan) and RIKEN Bioresource Center Cell Bank (Tsukuba, Japan).

Techniques: Expressing, Control, Quantitative RT-PCR, Western Blot, Transfection, Incubation, Software

Journal: Cancer Science

Article Title: Downregulation of 15‐hydroxyprostaglandin dehydrogenase by interleukin‐1β from activated macrophages leads to poor prognosis in pancreatic cancer

doi: 10.1111/cas.13467

Figure Lengend Snippet: Tumor‐associated macrophages are inversely correlated with pancreatic ductal adenocarcinoma ( PDAC ) cells harboring high 15‐hydroxyprostaglandin dehydrogenase (15‐ PGDH ) expression. A,B, Representative immunohistochemical ( IHC ) staining of 15‐ PGDH (upper panel) and CD 163 (lower panel) expression in high 15‐ PGDH (A) and low 15‐ PGDH (B) serial PDAC specimens. Scale bar = 200 μm. C, Graph showing Pearson's correlation between the expression of 15‐ PGDH and the number of CD 163‐positive cells in 107 PDAC patients. D, Schematic representation of the findings of this study. IL ‐1βR, interleukin‐1β receptor

Article Snippet: The human PDAC cell lines PK‐8 and S2‐013 were obtained from the Japanese Collection of Research Bioresource Cell Bank (Ibaraki, Japan) and RIKEN Bioresource Center Cell Bank (Tsukuba, Japan).

Techniques: Expressing, Immunohistochemical staining, Immunohistochemistry